The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.
 
Ibiayi Dagogo-Jack
Honoraria - Foundation Medicine
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Guardant Health; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Marguerite Rooney
No Relationships to Disclose
 
Rebecca Nagy
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Subba Digumarthy
No Relationships to Disclose
 
Emily Chin
No Relationships to Disclose
 
Jennifer Ackil
No Relationships to Disclose
 
Justin F. Gainor
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Jounce Therapeutics; Loxo; Merck; Oncorus; Regeneron; Takeda; Theravance
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Jessica Jiyeong Lin
Honoraria - Chugai Pharma
Consulting or Advisory Role - Boehringer Ingelheim
 
Richard B. Lanman
Employment - Guardant Health; Veracyte
Leadership - Biolase; Guardant Health
Stock and Other Ownership Interests - Biolase; Forward; Guardant Health
Speakers' Bureau - Forward
Research Funding - Guardant Health
 
Alice Tsang Shaw
Honoraria - Foundation medicine; Guardant Health; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Bayer; Blueprint Medicines; Chugai Pharma; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Loxo; Natera; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Takeda
Research Funding - ARIAD (Inst); Daiichi Sankyo (Inst); Ignyta (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); TP Therapeutics (Inst)